Navigation Links
Molecule May Trigger Psoriasis
Date:1/18/2008

Study in mice offers hope for new treatment of chronic skin disease

FRIDAY, Jan. 18 (HealthDay News) -- A molecule may play a major role in the development of psoriasis, offering a new way to treat this chronic skin disease, a study finds.

A team at Wyeth Research, in Cambridge, Mass., found that antibodies that neutralized the IL-22 molecule in mice prevented the development of psoriasis-like lesions. The researchers also found injecting IL-22 into the skin of normal mice activated genes associated with the development of psoriasis-like skin lesions.

These findings, published in the Jan. 17 issue of the Journal of Clinical Investigation, suggest that targeting IL-22 may provide a new approach to treating people with psoriasis, the study authors said.

Psoriasis, which causes red, scaly, raised skin lesions, affects up to 3 percent of the world's population and more than 7.5 million Americans, according to the National Psoriasis Association.

More information

The U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases has more about psoriasis.



-- Robert Preidt



SOURCE: Journal of Clinical Investigation, news release, Jan. 17, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1

Related medicine news :

1. Alzheimers molecule is a smart speed bump on the nerve-cell transport highway
2. Molecules might identify high-risk acute-leukemia patients
3. Common molecule notifies immune system of prostate cancer
4. Tiny RNA Molecules Control Breast Cancers Spread
5. Molecules can block breast cancers ability to spread
6. Major Advance in the Observation of DNA Molecules
7. St. Jude finds molecule that could improve cancer vaccines and therapy for other diseases
8. Jefferson neuroscientists show anti-inflammation molecule helps fight MS-like disease
9. Researchers identify molecules with interesting anti-clotting properties
10. Study Describes Molecules That Control Blood Pressure
11. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Molecule May Trigger Psoriasis
(Date:12/2/2016)... ... December 02, 2016 , ... "Pro3rd Accents Volume 2 is a ... versatile lower third titles with just a few clicks of the mouse," said Christina ... 30 lower third animations. Choose from various styles with accented animations, rigid boxes, simplistic ...
(Date:12/2/2016)... ... December 02, 2016 , ... Today CloudMine, a secure, cloud-based ... named the best Sales Team of 2016 as part of the 2016 SIIA ... the Software & Information Industry Association (SIIA), the principal trade association for the ...
(Date:11/30/2016)... ... 2016 , ... The Fertility Centers of New England ... Infertility Center of Excellence. The Cigna Center of Excellence recognizes participating infertility centers ... be designated a Cigna Infertility Center of Excellence," said Fertility Centers of New ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... Deloitte Wisconsin 75, an annual ranking and recognition of the largest closely held ... list, having ranked from 2008-2016. In addition, Standard Process was awarded the Talent ...
(Date:11/30/2016)... ... 2016 , ... In recent policy debates, increasing costs of ... and system stakeholders in many states. To help them understand this growth, today ... Workers’ Compensation, Eighth Edition (MPI-WC) . , “If you are a policymaker or ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... -- Eli Lilly and Company (NYSE: LLY ) ... updated financial guidance for 2016 on Thursday, December 15, ... that day with the investment community and media to ... conference call will begin at 10 a.m. ET. Investors, ... webcast of the conference call through a link that ...
(Date:12/2/2016)... MARLBOROUGH, Mass. , Dec. 2, 2016 ... announced a definitive agreement to acquire certain manufacturing assets ... NVCN ) (TSX: NVC) advanced biological tissue business, as ... a total of $75 million in cash. The Neovasc ... heart valves, including the Boston Scientific Lotus™ Valve System. ...
(Date:12/2/2016)... December 2, 2016 On Thursday, the ... in red, while the Dow Jones Industrial Average managed to ... of US markets, which prompted Stock-callers this morning to look ... (NASDAQ: NUVA ), Smith & Nephew PLC (NYSE: ... NXTM ), and Cesca Therapeutics Inc. (NASDAQ: KOOL ...
Breaking Medicine Technology: